MX2019015402A - Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso. - Google Patents
Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.Info
- Publication number
- MX2019015402A MX2019015402A MX2019015402A MX2019015402A MX2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- polypeptides
- mtsp
- inhibit
- disorders
- Prior art date
Links
- 101100069392 Mus musculus Gzma gene Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 title 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 230000024203 complement activation Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000002780 macular degeneration Diseases 0.000 abstract 3
- 102000000989 Complement System Proteins Human genes 0.000 abstract 2
- 108010069112 Complement System Proteins Proteins 0.000 abstract 2
- 208000021709 Delayed Graft Function Diseases 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21109—Matriptase (3.4.21.109)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
- Materials For Photolithography (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan polipéptidos MTSP-1 modificados que tienen actividad y/o especificidad alterada de manera que escinden una proteína de complemento, tal como la proteína de complemento C3, para inhibir su actividad y por ello inhibir la activación de complemento. Los polipéptidos MTSP-1 modificados que inhiben la activación de complemento pueden usarse para el tratamiento de enfermedades y afecciones en las cuales la activación de complemento juega un papel. Tales enfermedades y afecciones incluyen enfermedades inflamatorias y enfermedades con un componente inflamatorio. Los ejemplos de estos trastornos son trastornos isquémicos y por reperfusión, incluyendo infarto al miocardio y apoplejía, sepsis, enfermedades autoinmunitarias, enfermedades oftálmicas, tales como retinopatías diabéticas y degeneración macular, incluyendo degeneración macular relacionada con la edad (AMD), y rechazo al órgano trasplantado, tal como función retardada de injerto renal (DGF).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523735P | 2017-06-22 | 2017-06-22 | |
US201862664051P | 2018-04-27 | 2018-04-27 | |
PCT/US2018/038844 WO2018237201A1 (en) | 2017-06-22 | 2018-06-21 | MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015402A true MX2019015402A (es) | 2020-07-20 |
Family
ID=63015005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015402A MX2019015402A (es) | 2017-06-22 | 2018-06-21 | Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso. |
Country Status (18)
Country | Link |
---|---|
US (5) | US10781435B2 (es) |
EP (1) | EP3641801A1 (es) |
JP (3) | JP7091373B2 (es) |
KR (1) | KR102675270B1 (es) |
CN (1) | CN111107870A (es) |
AU (2) | AU2018290281B2 (es) |
BR (1) | BR112019027583A2 (es) |
CA (2) | CA3067851C (es) |
CL (3) | CL2019003813A1 (es) |
CO (1) | CO2020000584A2 (es) |
IL (2) | IL271587B2 (es) |
JO (1) | JOP20190288A1 (es) |
MX (1) | MX2019015402A (es) |
NZ (1) | NZ760116A (es) |
PE (1) | PE20200697A1 (es) |
PH (1) | PH12019502838A1 (es) |
SG (3) | SG10202110492YA (es) |
WO (1) | WO2018237201A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN111480345B (zh) | 2017-12-14 | 2022-04-29 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
US11396529B2 (en) * | 2020-11-12 | 2022-07-26 | National Sun Yat-Sen University | Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same |
AU2022205421A1 (en) * | 2021-01-08 | 2023-07-20 | Vertex Pharmaceuticals Incorporated | Factor b proteases |
CN113456527B (zh) * | 2021-07-30 | 2023-04-07 | 北京清大赛尔生物科技有限公司 | 一种nadh微胶囊制剂及其制备方法和应用 |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795A (en) | 1848-09-19 | Saddletree for carts | ||
US5990A (en) | 1848-12-26 | of baltimore | ||
US5324A (en) | 1847-10-09 | Cooking-stove | ||
US844A (en) | 1838-07-17 | Boiler for | ||
US237A (en) | 1837-06-15 | Egbert beale | ||
US569A (en) | 1838-01-09 | Caruiag-e-spiiln g | ||
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
CN1103782C (zh) | 1994-03-31 | 2003-03-26 | 安姆根有限公司 | 单聚乙二醇化的mgdf多肽 |
US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
EP1095243A2 (en) | 1998-07-03 | 2001-05-02 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
US6153394A (en) | 1998-09-18 | 2000-11-28 | Board Of Trustees Operating Michigan State University | Immunoassay for equine protozoal myeloencephalitis in horses |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
AU7497000A (en) | 1999-02-28 | 2000-11-14 | Washington University | Novel transduction molecules and methods for using same |
CA2362670A1 (en) | 1999-03-12 | 2000-09-14 | Georgetown University | Matriptase, a serine protease and its applications |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
WO2001032711A2 (en) | 1999-10-21 | 2001-05-10 | Board Of Trustees Of The University Of Arkansas | Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
KR100653153B1 (ko) | 1999-12-22 | 2006-12-01 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 수용성 중합체의 입체장애 유도체 |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
ATE367398T1 (de) | 2000-05-16 | 2007-08-15 | Bolder Biotechnology Inc | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
GB0103110D0 (en) | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
US7157596B2 (en) | 2000-09-08 | 2007-01-02 | Dendreon Corporation | Inhibitors of serine protease activity of matriptase or MTSP1 |
DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
AU2002305052A1 (en) | 2001-03-13 | 2002-09-24 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
US7105333B2 (en) | 2001-03-27 | 2006-09-12 | Deadreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
EP1539942A4 (en) | 2001-05-14 | 2005-10-19 | Dendreon Corp | A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF |
WO2002095007A2 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2002356824A1 (en) | 2001-10-19 | 2003-05-06 | The Scripps Research Institute | Novel methods for introducing molecules into cells and vectors and compositions for use in such methods |
US7026440B2 (en) | 2001-11-07 | 2006-04-11 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7192468B2 (en) | 2002-04-15 | 2007-03-20 | Fluor Technologies Corporation | Configurations and method for improved gas removal |
AU2003269880A1 (en) | 2002-05-21 | 2003-12-22 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon |
EP2444809A3 (en) | 2002-10-02 | 2013-07-24 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
US20060024289A1 (en) | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
EP2151507B1 (en) | 2002-12-20 | 2013-02-13 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
US20040147027A1 (en) | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US20060178297A1 (en) | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
AU2004215912B2 (en) | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 peg 유도체 |
US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
CA2529752A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
US7439226B2 (en) | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
KR100956913B1 (ko) | 2003-12-19 | 2010-05-11 | 제넨테크, 인크. | 치료제로서 유용한 일가 항체 단편 |
CA2562729C (en) | 2004-04-12 | 2013-11-12 | Sandra Waugh Ruggles | Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
US8173144B2 (en) | 2004-11-04 | 2012-05-08 | L'oreal | Administration of urea compounds for combating signs of cutaneous aging |
EP1851543A2 (en) | 2005-02-24 | 2007-11-07 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
AU2011218753B2 (en) * | 2005-10-21 | 2013-10-24 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
NZ595193A (en) | 2005-10-21 | 2013-09-27 | Catalyst Biosciences Inc | Modified Proteases That Inhibit Complement Activation |
EP1940865A2 (en) | 2005-11-01 | 2008-07-09 | Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University | Novel protein transduction domains and uses therefor |
US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
EP1991560B1 (en) | 2006-02-20 | 2018-04-04 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
EP1867661A1 (en) | 2006-06-12 | 2007-12-19 | Diatos | Compositions and methods for delivering anti-activated ras antibodies into cells |
CA2791144C (en) * | 2006-07-05 | 2019-04-09 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
EP2046951B1 (en) | 2006-07-05 | 2011-10-26 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thererby |
EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
WO2012021891A2 (en) | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits and methods for treatment of complement-related disorders |
US20140329252A1 (en) | 2011-10-14 | 2014-11-06 | Hopital Sainte-Justine | Methods and kits for diagnosing and/or prognosing osteoarthritis |
CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
JP2015513913A (ja) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ポリヌクレオチド |
US10029415B2 (en) | 2012-08-16 | 2018-07-24 | Stratasys, Inc. | Print head nozzle for use with additive manufacturing system |
CA2836167A1 (en) | 2013-12-10 | 2015-06-10 | Christina Xiaolin Dai | Thickness increase spring |
AU2015254913B2 (en) | 2014-04-29 | 2018-05-17 | Novartis Ag | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
TWI759810B (zh) | 2014-08-08 | 2022-04-01 | 美商Alx腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
AU2016209349B2 (en) | 2015-01-20 | 2020-05-07 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the Androgen Receptor |
US11191844B2 (en) | 2015-07-06 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
US11903996B2 (en) | 2015-10-07 | 2024-02-20 | David C. Fritzinger | Modulators of complement function |
JP2018531983A (ja) | 2015-11-02 | 2018-11-01 | イエール ユニバーシティ | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 |
BR112021012601A2 (pt) | 2018-12-28 | 2021-11-30 | Catalyst Biosciences Inc | Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso |
-
2018
- 2018-06-21 CA CA3067851A patent/CA3067851C/en active Active
- 2018-06-21 IL IL271587A patent/IL271587B2/en unknown
- 2018-06-21 EP EP18746035.7A patent/EP3641801A1/en active Pending
- 2018-06-21 SG SG10202110492YA patent/SG10202110492YA/en unknown
- 2018-06-21 KR KR1020207001850A patent/KR102675270B1/ko active IP Right Grant
- 2018-06-21 MX MX2019015402A patent/MX2019015402A/es unknown
- 2018-06-21 IL IL308949A patent/IL308949A/en unknown
- 2018-06-21 CA CA3177086A patent/CA3177086A1/en active Pending
- 2018-06-21 SG SG11201912071QA patent/SG11201912071QA/en unknown
- 2018-06-21 JP JP2019571004A patent/JP7091373B2/ja active Active
- 2018-06-21 AU AU2018290281A patent/AU2018290281B2/en active Active
- 2018-06-21 NZ NZ760116A patent/NZ760116A/en unknown
- 2018-06-21 PE PE2019002621A patent/PE20200697A1/es unknown
- 2018-06-21 SG SG10202110500TA patent/SG10202110500TA/en unknown
- 2018-06-21 US US16/015,093 patent/US10781435B2/en active Active
- 2018-06-21 CN CN201880053998.8A patent/CN111107870A/zh active Pending
- 2018-06-21 BR BR112019027583-5A patent/BR112019027583A2/pt unknown
- 2018-06-21 WO PCT/US2018/038844 patent/WO2018237201A1/en active Search and Examination
- 2018-12-22 JO JOP/2019/0288A patent/JOP20190288A1/ar unknown
-
2019
- 2019-12-16 PH PH12019502838A patent/PH12019502838A1/en unknown
- 2019-12-23 CL CL2019003813A patent/CL2019003813A1/es unknown
-
2020
- 2020-01-20 CO CONC2020/0000584A patent/CO2020000584A2/es unknown
- 2020-06-02 US US16/890,936 patent/US10954501B2/en active Active
- 2020-10-08 US US17/066,398 patent/US11401513B2/en active Active
-
2021
- 2021-07-09 US US17/371,980 patent/US11807882B2/en active Active
- 2021-11-22 CL CL2021003080A patent/CL2021003080A1/es unknown
- 2021-11-22 CL CL2021003081A patent/CL2021003081A1/es unknown
-
2022
- 2022-03-02 AU AU2022201445A patent/AU2022201445B2/en active Active
- 2022-06-15 JP JP2022096844A patent/JP2022120155A/ja active Pending
-
2023
- 2023-08-16 US US18/450,994 patent/US20240018502A1/en active Pending
-
2024
- 2024-03-13 JP JP2024038624A patent/JP2024095662A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502838A1 (en) | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use | |
FR3046421B1 (fr) | Procede de fabrication de substituts cutanes par depot additif | |
WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
TWD183558S (zh) | 耳環 | |
TWD189856S (zh) | 耳環 | |
TWD177952S (zh) | 耳環 | |
TWD186176S (zh) | 耳環 | |
MA40132B1 (fr) | Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li | |
SG10201808258SA (en) | Improved methods for manufacturing adoptive cell therapies | |
TWD182267S (zh) | 垂飾 | |
TWD176804S (zh) | 垂飾 | |
TWD169415S (zh) | 耳環 | |
MX2021003475A (es) | Metodos de purificacion de proteinas. | |
AU2016255474A8 (en) | Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease | |
EA202091325A1 (ru) | Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток | |
MY197672A (en) | Room temperature stable lyophilized protein | |
WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
JOP20210146A1 (ar) | بولي ببتيدات منشط بلازمينوجين من نوع يوروكيناز معدلة وطرق استخدامها | |
WO2021041592A8 (en) | Methods of treating vascular diseases | |
CO2021012267A2 (es) | Composiciones de materia con actividad para eliminar lipofuscina de células retinales | |
GB2530224A (en) | Enhancement of osteogenic potential of bone grafts | |
EA202000017A1 (ru) | Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения | |
TWD203628S (zh) | 耳釘 | |
TWD218442S (zh) | 耳釘 | |
TWD218439S (zh) | 耳釘 |